High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$72.1M
$72,053,306
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
AXSM
S
Axsome Therapeutics, Inc.
Coleman Mark
• Director
10b5-1 SellΔOwn -34.6%
2026-02-26
$4,027,750Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -34.6%
|
2026-02-26 | $4,027,750Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
COO
Other
|
2026-02-26 | $100,827 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
COO
10b5-1 Sell
|
2026-02-26 | $5,726,991Whale | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
Director
Other
|
2026-02-23 | $30,938 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
Director
Other
|
2026-02-20 | $61,801 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
Director
Other
|
2026-02-10 | $41,648 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2026-02-02 | $259,928 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -81.8%
2026-02-02
$6,015,296Whale
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -81.8%
|
2026-02-02 | $6,015,296Whale | S | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
Pizzie Nick
• CFO
10b5-1 SellΔOwn -22.0%
2026-01-22
$2,255,040Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CFO
10b5-1 SellΔOwn -22.0%
|
2026-01-22 | $2,255,040Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CFO
Other
|
2026-01-22 | $42,000 | M | Form 4 |
|
AXSM
M
Axsome Therapeutics, Inc.
Maizel Ari
• Officer • Chief Commercial Officer
Other
2026-01-21
$530,475
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
Officer • Chief Commercial Officer
Other
|
2026-01-21 | $530,475 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
Maizel Ari
• Officer • Chief Commercial Officer
10b5-1 Sell
2026-01-21
$1,383,300Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
Officer • Chief Commercial Officer
10b5-1 Sell
|
2026-01-21 | $1,383,300Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Equity Compensation
|
2025-12-04 | $0 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-12-04 | $84,675 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -59.4%
2025-12-04
$1,564,484Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -59.4%
|
2025-12-04 | $1,564,484Large | S | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -73.6%
2025-12-03
$2,962,751Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -73.6%
|
2025-12-03 | $2,962,751Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-12-03 | $161,707 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Equity Compensation
|
2025-12-03 | $0 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-12-02 | $395,001 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -87.2%
2025-12-02
$7,121,347Whale
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -87.2%
|
2025-12-02 | $7,121,347Whale | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Equity Compensation
|
2025-12-02 | $0 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-11-05 | $174,636 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -75.1%
2025-11-05
$2,928,520Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -75.1%
|
2025-11-05 | $2,928,520Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-11-04 | $404,681 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -87.5%
2025-11-04
$6,750,910Whale
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -87.5%
|
2025-11-04 | $6,750,910Whale | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-11-03 | $735,474 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -92.7%
2025-11-03
$12,136,240MEGA
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -92.7%
|
2025-11-03 | $12,136,240MEGA | S | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -63.9%
2025-10-08
$1,518,062Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -63.9%
|
2025-10-08 | $1,518,062Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-10-08 | $102,447 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-10-07 | $107,388 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -64.9%
2025-10-07
$1,590,330Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -64.9%
|
2025-10-07 | $1,590,330Large | S | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -72.7%
2025-10-06
$2,309,667Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -72.7%
|
2025-10-06 | $2,309,667Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-10-06 | $154,144 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
COO
Other
|
2025-09-22 | $28,500 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
COO
10b5-1 Sell
|
2025-09-22 | $1,159,600Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-09-16 | $158,146 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -73.2%
2025-09-16
$2,251,713Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -73.2%
|
2025-09-16 | $2,251,713Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
COO
Other
|
2025-09-16 | $72,750 | M | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
COO
10b5-1 Sell
|
2025-09-16 | $4,569,200Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
COO
10b5-1 Sell
|
2025-09-16 | $671,927 | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
COO
Other
|
2025-09-16 | $123,750 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -67.8%
2025-09-15
$1,790,362Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -67.8%
|
2025-09-15 | $1,790,362Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-09-15 | $122,337 | M | Form 4 |
|
AXSM
S
Axsome Therapeutics, Inc.
TABUTEAU HERRIOT
• CEO
10b5-1 SellΔOwn -79.4%
2025-09-12
$3,319,817Large
|
||||||
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -79.4%
|
2025-09-12 | $3,319,817Large | S | Form 4 |
| AXSM |
Axsome Therapeutics, Inc.
|
CEO
Other
|
2025-09-12 | $223,814 | M | Form 4 |